Observational Study of PBC Patients Treated With Seladelpar in Germany and Switzerland
Summary
NIH's ClinicalTrials.gov registry published NCT07549607, an observational study evaluating real-world clinical data for patients diagnosed with Primary Biliary Cirrhosis (PBC) who are treated with Seladelpar. The seladelpar registry will collect data from patients in Germany and Switzerland under real-life treatment conditions. This registry entry documents a clinical investigation rather than imposing regulatory obligations on affected parties.
“The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registry entry documents NCT07549607, an observational study to characterize patients with Primary Biliary Cirrhosis treated with Seladelpar in a real-life setting. The study will collect data from clinical practice in Germany and Switzerland, tracking patient outcomes under standard treatment conditions rather than controlled clinical trial protocols. No regulatory obligations or compliance requirements are established by this registry entry; it serves as a public record of ongoing clinical research activity.
Affected parties including healthcare providers, clinical investigators, and patients in Germany and Switzerland should be aware that Seladelpar for PBC is being monitored through a formal registry program. Pharmaceutical manufacturers and clinical researchers conducting real-world evidence studies may find this registry a model for post-marketing surveillance of hepatic therapies.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
Observational NCT07549607 Kind: OBSERVATIONAL Apr 24, 2026
Abstract
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
Conditions: Primary Bilary Cirrhosis (PBC)
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.